MicroRNA Expression of Primary and Metastatic Colorectal and Breast Carcinoma
Article Sidebar
Main Article Content
Abstract
Background: Colorectal and breast carcinoma are frequently diagnosed cancers. At advanced stages, cancers metastasize to certain organs resulting in loss of function of these organs, and eventually death. Therefore, there is a specific need for the prognosis of these cancers. Currently, microRNAs (miRNAs), have emerged as a new target of cancer-specific biomarker.
Objective: To examine the expression of miRNA in primary and metastatic breast and colorectal cancers.
Methods: This study investigated the expression of 6 miRNAs (miR-10b, miR-21, miR-145, miR-155, miR-200c, and miR-373) in formalin fixed paraffin embed tissues from pairs of normal tissues with primary and metastatic tumor samples of breast and colorectal carcinoma cases in Ramathibodi Hospital, Thailand by real-time RT-PCR.
Results: Among 6 miRNAs, miR-145 decreased significantly in all samples of primary and metastatic colorectal and breast carcinoma. There was significantly decreased expression of miR-145 in metastatic colorectal carcinoma compared to their primary colorectal carcinoma (P < .05). Whereas miR-10b, miR-155, and miR-200c showed a decreased expression; miR-21, and miR-373 showed an increased expression in the majority of cases. Unlike miR-145, other miRNAs showed no significant difference of expression (P > .05).
Conclusions: This finding indicates that miR-145 may be the potential metastatic biomarker. Decrease of miR-145 could be applied to the prognosis and target for therapy of breast and colorectal carcinoma.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Fact sheets: Cancer. World Health Organization; 2021. Update February 3, 2022. Accessed April 15, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
Heydarzadeh S, Ranjbar M, Karimi F, Seif F, Alivand MR. Overview of host miRNA properties and their association with epigenetics, long non-coding RNAs, and Xeno-infectious factors. Cell Biosci. 2021;11(1):43. doi:10.1186/s13578-021-00552-1
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105. doi:10.1101/gr.082701.108
Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol. 2011;724:259-267. doi:10.1007/978-1-61779-055-3_16
Nishida N, Yamashita S, Mimori K, et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012;19(9):3065-3071. doi:10.1245/s10434-012-2246-1
Hunsaker M, Barba G, Kingsley K, Howard KM. Differential microRNA expression of miR-21 and miR-155 within oral cancer extracellular vesicles in response to melatonin. Dent J (Basel). 2019;7(2):48. doi:10.3390/dj7020048
Dynoodt P, Speeckaert R, De Wever O, et al. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol. 2013;42(4):1443-1451. doi:10.3892/ijo.2013.1823
Bojmar L, Karlsson E, Ellegård S, et al. The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One. 2013;8(12):e84815. doi:10.1371/journal.pone.0084815
Wei F, Cao C, Xu X, Wang J. Diverse functions of miR-373 in cancer. J Transl Med. 2015;13:162. doi:10.1186/s12967-015-0523-z
Li S, Fu H, Wang Y, et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology. 2009;49(4):1194-1202. doi:10.1002/hep.22757
Li W, Chang J, Tong D, et al. Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. Oncotarget. 2017;8(22):35783-35791. doi:10.18632/oncotarget.16206
Tsai HP, Huang SF, Li CF, Chien HT, Chen SC. Differential microRNA expression in breast cancer with different onset age. PLoS One. 2018;13(1):e0191195. doi:10.1371/journal.pone.0191195
Li C, Yan G, Yin L, Liu T, Li C, Wang L. Prognostic roles of microRNA 143 and microRNA 145 in colorectal cancer: a meta-analysis. Int J Biol Markers. 2019;34(1):6-14. doi:10.1177/1724600818807492
Shen X, Jiang H, Chen Z, et al. MicroRNA-145 inhibits cell migration and invasion in colorectal cancer by targeting TWIST. Onco Targets Ther. 2019;12:10799-10809. doi:10.2147/OTT.S216147
Wang W, Ji G, Xiao X, et al. Epigenetically regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1. Oncotarget. 2016;7(42):68674-68687. doi:10.18632/oncotarget.11919
Qin J, Wang F, Jiang H, Xu J, Jiang Y, Wang Z. MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Pathol. 2015;8(2):1328-1340.
Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18(10):1913-1926. doi:10.1111/jcmm.12358
Huang Q, Song Q, Zhong W, Chen Y, Liang L. MicroRNA-10b and the clinical outcomes of various cancers: a systematic review and meta-analysis. Clin Chim Acta. 2017;474:14-22. doi:10.1016/j.cca.2017.08.034
Ma H, Marti-Gutierrez N, Park SW, et al. Ma et al. reply. Nature. 2018;560(7717):E10-E23. doi:10.1038/s41586-018-0381-y
Sheedy P, Medarova Z. The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res. 2018;8(9):1674-1688.
Nishida N, Yamashita S, Mimori K, et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012;19(9):3065-3071. doi:10.1245/s10434-012-2246-1
Jiang H, Liu J, Chen Y, Ma C, Li B, Hao T. Up-regulation of mir-10b predicate advanced clinicopathological features and liver metastasis in colorectal cancer. Cancer Med. 2016;5(10):2932-2941. doi:10.1002/cam4.789
Vychytilova-Faltejskova P, Pesta M, Radova L, et al. Genome-wide microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. Cancer Genomics Proteomics. 2016;13(4):311-316.
Huang CS, Yu W, Cui H, et al. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8(6):7234-7238.
He Y, Zhang L, Cheng G, et al. Upregulation of circulating miR-21 is associated with poor prognosis of nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2017;10(7):7362-7368.
Kong W, He L, Richards EJ, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679-689. doi:10.1038/onc.2012.636
Senfter D, Madlener S, Krupitza G, Mader RM. The microRNA-200 family: still much to discover. Biomol Concepts. 2016;7(5-6):311-319. doi:10.1515/bmc-016-0020
Kumar S, Nag A, Mandal CC. A comprehensive review on miR-200c, a promising cancer biomarker with therapeutic potential. Curr Drug Targets. 2015;16(12):1381-1403. doi:10.2174/1389450116666150325231419
Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169-1181. doi:10.1016/j.cell.2006.02.037
Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10(2):202-210. doi:10.1038/ncb1681